


TELECOPIER TRANSMISSION



BRISTOL-MYERS SQUIBB COMPANY
Legal Division
P.O. Box 5100
5 Research Parkway
Wallingford, CT 06492-7660

FAX RECEIVED

MAR 24 2003

GROUP 1600

OFFICIAL

TO: Examiner Rebecca L. Anderson (USPTO) Washington, DC	
TELECOPIER NO: 9-1-703-308-4242	
FROM: S. J. DuBoff	
TELECOPIER NO: 203-677-6900	
TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 3	
DATE: 3/21/03	

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Samuel J. DuBoff
Type or print name

Samuel J. DuBoff
Signature

March 21, 2003
Date

7 A
Ver
3-26-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

EXAMINER: Rebecca L. Anderson

Amy Qi Han, et al

ART UNIT: 1626

APPLICATION NO: 10/015,328

FILED: December 12, 2001

FOR: IMIDAZOLIDINONES AND THEIR RELATED DERIVATIVES AS
HEPATITIS C VIRUS NS3 PROTEASE INHIBITORSAssistant Commissioner for Patents
Washington, D.C. 20231**RESPONSE TO RESTRICTION
AND ELECTION REQUIREMENTS**

Sir:

This is in response to the Office Action mailed February 24, 2003 in the above-identified application which is due for response on March 24, 2003.

AMENDMENTS

Kindly cancel claims 14-22.

RESTRICTION/ELECTION OF SPECIES REQUIREMENTS

Claims 1-22, the claims pending in the application, have been made the subject of a restriction requirement.


Applicant respectfully elects Group I (claims 1-13) with traverse in the present application. Claims 14-22 have been cancelled since they apply to non-elected Group II.

Docket PH-7203
US6N 10/015,328
Filed December 12, 2001
Page 2

Applicant hereby elects the compound of Example 1 in Table 1 as the single disclosed species.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7787



Samuel J. DuBoff
Attorney for Applicant
Reg. No. 25,969

Date: 3/21/03